We are live on ! Find out more
DCMIC

Decheng Capital Management III (Cayman) Portfolio holdings

AUM $300M
1-Year Est. Return 15.74%
This Fund
S&P 500
This Quarter Est. Return
+3.72%
1 Year Est. Return
+15.74%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$248M
AUM Growth
-$19.3M
Cap. Flow
-$17.3M
Cap. Flow %
-6.97%
Top 10 Hldgs %
83.16%
Holding
28
New
2
Increased
1
Reduced
1
Closed
4

Top Buys

Rank Stock Value
1
BYSI icon
BeyondSpring
BYSI
+$9.6M
2
ARGX icon
argenx
ARGX
+$8.11M
3
ATRC icon
AtriCure
ATRC
+$1.92M

Top Sells

Rank Stock Value
1
ALBO
Albireo Pharma Inc
ALBO
+$13.5M
2
RXDX
Prometheus Biosciences, Inc. Common Stock
RXDX
+$11.5M
3
NAUT icon
Nautilus Biotechnolgy
NAUT
+$540K

Sector Composition

Rank Sector Weight
1 Healthcare 79.11%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ALP.PRN
1
DELISTED
Alabama Power Co 5.20% CL-A PRF
ALP.PRN
$51.8M 20.89%
6,708,288
– –
ZNTL icon
2
Zentalis Pharmaceuticals
ZNTL
$302M
$31.4M 12.66%
1,824,583
– –
TXG icon
3
10x Genomics
TXG
$6.61B
$20.1M 8.09%
359,554
– –
ILMN icon
4
Illumina
ILMN
$28.4B
$18.8M 7.59%
83,123
– –
PACB icon
5
Pacific Biosciences
PACB
$370M
$17M 6.84%
1,463,872
– –
HLTH
6
DELISTED
Cue Health Inc. Common Stock
HLTH
$16.3M 6.59%
8,980,909
– –
RXDX
7
DELISTED
Prometheus Biosciences, Inc. Common Stock
RXDX
$16.1M 6.49%
150,000
-100,000
-40% -$11.5M
RCUS icon
8
Arcus Biosciences
RCUS
$3.64B
$15.9M 6.4%
869,790
– –
ARGX icon
9
argenx
ARGX
$54.1B
$10.2M 4.12%
27,429
+21,900
+396% +$8.11M
HZNP
10
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$8.61M 3.47%
78,900
– –
TERN
11
DELISTED
Terns Pharmaceuticals
TERN
$8.46M 3.41%
714,285
– –
BYSI icon
12
BeyondSpring
BYSI
$35.8M
$5.55M 2.24%
+4,958,143
New +$9.6M
SGEN
13
DELISTED
Seagen Inc. Common Stock
SGEN
$4.66M 1.88%
23,014
– –
WHWK
14
Whitehawk Therapeutics
WHWK
$271M
$3.81M 1.54%
526,329
– –
MRSN
15
DELISTED
Mersana Therapeutics
MRSN
$3.72M 1.5%
36,171
– –
ACET icon
16
Adicet Bio
ACET
$74.7M
$3.34M 1.35%
36,250
– –
EQ icon
17
Equillium
EQ
$133M
$3.25M 1.31%
4,447,308
– –
AURA icon
18
Aura Biosciences
AURA
$826M
$2.72M 1.1%
293,333
– –
ATRC icon
19
AtriCure
ATRC
$2.11B
$1.92M 0.77%
+46,259
New +$1.92M
SCYX icon
20
SCYNEXIS
SCYX
$52M
$1.67M 0.67%
69,444
– –
WGS icon
21
GeneDx Holdings
WGS
$2.3B
$1.25M 0.5%
103,604
– –
APGN
22
DELISTED
Apexigen, Inc. Common Stock
APGN
$923K 0.37%
1,894,551
– –
OWLT icon
23
Owlet
OWLT
$160M
$291K 0.12%
64,171
– –
NBSE
24
DELISTED
NeuBase Therapeutics, Inc. Common Stock
NBSE
$185K 0.07%
50,000
– –
NAUT icon
25
Nautilus Biotechnolgy
NAUT
$115M
– –
-300,000
Closed -$540K
1
2

Similar funds

IBT
International Biotechnology Trust London, United Kingdom $297M AUM 17.25% 1-Year Est. Return
3LCM
3D/L Capital Management Hartford, Connecticut $308M AUM 13.67% 1-Year Est. Return
DT
Daniels + Tansey Wilmington, Delaware $289M AUM 18.06% 1-Year Est. Return
SFG
Steward Financial Group Colleyville, Texas $315M AUM 13.78% 1-Year Est. Return
TFA
Triad Financial Advisors Greensboro, North Carolina $284M AUM 14.95% 1-Year Est. Return
AEPLI
AH Equity Partners LSV I Menlo Park, California $315M AUM 9.31% 1-Year Est. Return
CC
Chanos & Company New York $318M AUM 4.62% 1-Year Est. Return
KBC
Key Bridge Compliance $319M AUM

Decheng Capital Management III (Cayman)'s Q1 2023 Portfolio in Review

As of Q1 2023, Decheng Capital Management III (Cayman) held 28 positions worth $248M, down 7.2% from $267M the previous quarter. Its ten largest holdings account for 83% of the portfolio.

Decheng Capital Management III (Cayman) withdrew a net $17.3M in Q1 2023, closing 4 positions and reducing 1 holding. Its most notable exit was Albireo Pharma Inc, an estimated $13.5M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 79% of assets, up from 77% a quarter earlier.

Against the trend, Decheng Capital Management III (Cayman) opened a new position in BeyondSpring worth $5.55M.

  • Decheng Capital Management III (Cayman)'s largest Q1 2023 buy was BeyondSpring: 4,958,143 shares worth $5.55M.
  • Decheng Capital Management III (Cayman) added most to argenx in Q1 2023, an estimated $8.11M increase.
  • Decheng Capital Management III (Cayman)'s biggest Q1 2023 reduction was Prometheus Biosciences, Inc. Common Stock, cutting an estimated $11.5M.
  • Decheng Capital Management III (Cayman) fully exited Albireo Pharma Inc in Q1 2023, selling an estimated $13.5M.
  • Decheng Capital Management III (Cayman)'s ten largest holdings make up 83% of its $248M portfolio in Q1 2023.
  • Decheng Capital Management III (Cayman) opened 2 new positions and closed 4 in Q1 2023.
  • Decheng Capital Management III (Cayman)'s portfolio value fell 7.2% quarter-over-quarter to $248M.

Based on Decheng Capital Management III (Cayman)'s 13F filing for Q1 2023, filed 10 May 2023.